High-Grade Gliomas in Children with Neurofibromatosis Type 1: Literature Review and Illustrative Cases

References

1. 1.↵
   2. Rodriguez FJ,
   3. Perry A,
   4. Gutmann DH, et al

   . Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008;67:240–49 doi:10.1097/NEN.0b013e318165eb75 pmid:18344915

   CrossRefPubMed
2. 2.↵
   2. Fangusaro J

   . Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol 2012;2:105 doi:10.3389/fonc.2012.00105 pmid:22937526

   CrossRefPubMed
3. 3.↵
   2. Byrne S,
   3. Connor S,
   4. Lascelles K, et al

   . Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas. J Neurooncol 2017;133:609–14 doi:10.1007/s11060-017-2475-z pmid:28593402

   CrossRefPubMed
4. 4.↵
   2. Blatt J,
   3. Jaffe R,
   4. Deutsch M, et al

   . Neurofibromatosis and childhood tumors. Cancer 1986;57:1225–29 doi:10.1002/1097-0142(19860315)57:6<1225::AID-CNCR2820570627>3.0.CO;2-P pmid:3080222

   CrossRefPubMed
5. 5.↵
   2. Gutmann DH,
   3. Rasmussen SA,
   4. Wolkenstein P, et al

   . Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 2002;59:759–61 doi:10.1212/WNL.59.5.759 pmid:12221173

   Abstract/FREE Full Text
6. 6.↵
   2. Upadhyay N,
   3. Waldman AD

   . Conventional MRI evaluation of gliomas. Br J Radiol 2011;84(Spec No 2):S107–11 doi:10.1259/bjr/65711810 pmid:22433821

   Abstract/FREE Full Text
7. 7.↵
   2. Hilario A,
   3. Ramos A,
   4. Perez-Nuñez A, et al

   . The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol 2012;33:701–07 doi:10.3174/ajnr.A2846 pmid:22207304

   Abstract/FREE Full Text
8. 8.↵
   2. Kao HW,
   3. Chiang SW,
   4. Chung HW, et al

   . Advanced MR imaging of gliomas: an update. Biomed Res Int 2013;2013:970586 doi:10.1155/2013/970586 pmid:23862163

   CrossRefPubMed
9. 9.↵
   2. Sugahara T,
   3. Korogi Y,
   4. Kochi M, et al

   . Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53–60 doi:10.1002/(SICI)1522-2586(199901)9:1<53::AID-JMRI7>3.0.CO;2-2 pmid:10030650

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Panigrahy A,
    3. Blüml S

    . Neuroimaging of pediatric brain tumors: from basic to advanced magnetic resonance imaging (MRI). J Child Neurol 2009 24:1343–65 doi:10.1177/0883073809342129 pmid:19841424

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Muragaki Y,
    3. Chernov M,
    4. Maruyama T, et al

    . Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg 2008;51:275–79 doi:10.1055/s-0028-1082322 pmid:18855292

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Ginsberg LE,
    3. Fuller GN,
    4. Hashmi M, et al

    . The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998;49:436–40 doi:10.1016/S0090-3019(97)00360-1 pmid:9537664

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Gold DR,
    3. Cohen BH

    . Brain tumors in neurofibromatosis. Curr Treat Options Neurol 2003;5:199–206 doi:10.1007/s11940-003-0010-3 pmid:12670408

    CrossRefPubMed
14. 14.↵
    2. Kondziolka D,
    3. Lunsford LD,
    4. Martinez AJ

    . Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 1993;79:533–36 pmid:8410222

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Adam MP,
    2. Ardinger HH,
    3. Pagon RA,
    4. Wallace SE,
    5. Bean LJH,
    6. Stephens K,
    7. Amemiya A

    2. Friedman JM

    . Neurofibromatosis 1. 1998 October 2, Updated 2018 May 17Accessed December 2, 2018. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds. GeneReviews. Seattle, WA: University of Washington; 1993–2018. https://www.ncbi.nlm.nih.gov/books/NBK1109/. Accessed December 2, 2018.
16. 16.↵
    2. Pierallini A,
    3. Bonamini M,
    4. Bozzao A, et al

    . Supratentorial diffuse astrocytic tumours: proposal of an MRI classification. Eur Radiol 1997;7:395–99 doi:10.1007/s003300050173 pmid:9087364

    CrossRefPubMed
17. 17.↵
    2. Qi C,
    3. Yang S,
    4. Meng L, et al

    . Evaluation of cerebral glioma using 3T diffusion kurtosis tensor imaging and the relationship between diffusion kurtosis metrics and tumor cellularity. J Int Med Res 2017;45:1347–58 doi:10.1177/0300060517712654 pmid:28587542

    CrossRefPubMed
18. 18.↵
    2. Miaux Y,
    3. Guermazi A,
    4. Cornu P, et al

    . High-intensity lesion on T1-weighted MR images in neurofibromatosis type 1: a case of premalignant lesion. Acta Neurochir (Wien) 1997;139:1085–87 doi:10.1007/BF01411565 pmid:9442225

    CrossRefPubMed
19. 19.↵
    2. Distelmaier F,
    3. Fahsold R,
    4. Reifenberger G, et al

    . Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Childs Nerv Syst 2007;23:343–37 doi:10.1007/s00381-006-0222-4 pmid:17009007

    CrossRefPubMed
20. 20.↵
    2. Mistry M,
    3. Zhukova N,
    4. Merico D, et al

    . BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 2015;33:1015–22 doi:10.1200/JCO.2014.58.3922 pmid:25667294

    Abstract/FREE Full Text
21. 21.↵
    2. Mukasa A,
    3. Aihara K,
    4. Gotoh K, et al

    . Frequent H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol 2014;16:140–46 doi:10.1093/neuonc/not144 pmid:24285547

    CrossRefPubMed
22. 22.↵
    2. Neal MT,
    3. Ellis TL,
    4. Stanton CA

    . Pleomorphic xanthoastrocytoma in two siblings with neurofibromatosis type 1 (NF-1). Clin Neuropathol 2012;31:54–56 doi:10.5414/NP300424 pmid:22192706

    CrossRefPubMed
23. 23.↵
    2. Prayson RA

    . Pleomorphic xanthoastrocytoma arising in neurofibromatosis type 1. Clin Neuropathol 2012;31:152–54 doi:10.5414/NP300436 pmid:22551920

    CrossRefPubMed
24. 24.↵
    2. Takei H,
    3. Rouah E,
    4. Bhattacharjee MB

    . Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1: a case report and literature review. Int J Clin Exp Pathol 2015;8:7570–74 pmid:26261671

    PubMed
25. 25.↵
    2. Mackay A,
    3. Burford A,
    4. Molinari V, et al

    . Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY Phase II randomized trial. Cancer Cell 2018;33:829–42 doi:10.1016/j.ccell.2018.04.004 pmid:29763623

    CrossRefPubMed
26. 26.↵
    2. Callovini GM

    . Is it appropriate to redefine the indication for stereotactic brain biopsy in the MRI era? Correlation with final histological diagnosis in supratentorial gliomas. Minim Invasive Neurosurg 2008;51:109–13 doi:10.1055/s-2008-1058096 pmid:18401825

    CrossRefPubMed
27. 27.↵
    2. Huttner AJ,
    3. Kieran MW,
    4. Yao X, et al

    . Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer 2010;54:890–96 doi:10.1002/pbc.22462 pmid:20310005

    CrossRefPubMed